-
Mashup Score: 75
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: – Cilta-cel (or chimeric antigen receptor T cells) – Cyclophosphamide (a lymphodepleting chemotherapy) – Fludarabine (a lymphodepleting chemotherapy)
Source: www.dana-farber.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 73
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: – Cilta-cel (or chimeric antigen receptor T cells) – Cyclophosphamide (a lymphodepleting chemotherapy) – Fludarabine (a lymphodepleting chemotherapy)
Source: www.dana-farber.orgCategories: General Medicine News, Hem/OncsTweet-
The US medical system in all its glory! You can you be completely healthy, get a lab test checked you never needed, and end up receiving a toxic million dollar therapy with risks of secondary cancers and long term neurologic side effects. CAR-PRISM https://t.co/OGkPp1s431
-
-
Mashup Score: 36Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma - 2 month(s) ago
Key Points. SOC cilta-cel in RRMM results in deep and durable response despite over half the patients not meeting CARTITUDE-1 eligibility criteria.Close su
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Cilta cel in real world 10% non relapse mortality with only 13 month follow up. Sounds like an excellent drug for smoldering myeloma and frontline Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma https://t.co/x1m8kiywwv
-
-
Mashup Score: 2ClinicalTrials.gov - 3 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
@VincentRK @MayoMyeloma Do you still recommend enrolling in the ADVANCE study? https://t.co/AJpsboFkFx
-
-
Mashup Score: 2ClinicalTrials.gov - 3 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
@VincentRK @MayoMyeloma Do you still recommend enrolling in the ADVANCE study? https://t.co/AJpsboFkFx
-
-
Mashup Score: 162Dietary interventions in cancer: a systematic review of all randomized controlled trials - PubMed - 3 month(s) ago
Most RCTs of dietary interventions in cancer are small and measure non-clinical endpoints. Although only a small number of large RCTs have been conducted to date, these trials have not shown an improvement in cancer outcomes. Currently, there is limited evidence to support dietary interventions as a …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Dietary interventions in cancer: a systematic review of all randomized controlled trials! @ManniMD1 Randomized trials to date have NOT shown improvement in cancer outcomes. Eat healthy. Don't tell patients eating healthy will fight their cancer. https://t.co/a4K8TddozR
-
-
Mashup Score: 36Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma - 3 month(s) ago
Key Points. SOC cilta-cel in RRMM results in deep and durable response despite over half the patients not meeting CARTITUDE-1 eligibility criteria.Close su
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Cilta cel in real world 10% non relapse mortality with only 13 month follow up. Sounds like an excellent drug for smoldering myeloma and frontline Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma https://t.co/x1m8kiywwv
-
-
Mashup Score: 3Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials - PubMed - 3 month(s) ago
From the findings of this study, an estimated 11 months appeared to be needed (ie, approximately 12% longer in the drug development cycle) to assess the OS benefit of a cancer drug. This study’s findings suggest that this must be weighed against the downside of increased uncertainty of clinical bene …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hematologists1Tweet-
@rubinstein_md @oncology_bg @DrLesterColl @JCO_ASCO @csoncol @EAEisenhauer @ian_tannock this statement is not true see paper by @VPrasadMDMPH https://t.co/uGQvTwhbW3
-
-
Mashup Score: 34Vitamin D Supplementation and Prevention of Type 2 Diabetes | NEJM - 3 month(s) ago
Original Article from The New England Journal of Medicine — Vitamin D Supplementation and Prevention of Type 2 Diabetes
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Vitamin D does not prevent type 2 diabetes https://t.co/vJaNCgSH4H
-
-
Mashup Score: 586World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management - 3 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hematologists1Tweet-
I see a few referrals a year for eosinophilia. I always just follow this algorithm and think. Always rule out secondary: Parasite Lymphoma Collagen vascular dz ⬇️Adrenal Meds Allergy If above negative then time for fun and do a marrow bx. https://t.co/pE9PALJiIa https://t.co/wO9EwBUmL3
-
The US medical system in all its glory! You can you be completely healthy, get a lab test checked you never needed, and end up receiving a toxic million dollar therapy with risks of secondary cancers and long term neurologic side effects. CAR-PRISM https://t.co/OGkPp1s431